Antibiotic Polymeric Nanoparticles for Biofilm-Associated Infection Therapy

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1147)

Abstract

Polymeric nanoparticles are highly attractive as drug delivery vehicles due to their high structural integrity, stability during storage, ease of preparation and functionalization, and controlled release capability. Similarly, lipid–polymer hybrid nanoparticles, which retain the benefits of polymeric nanoparticles plus the enhanced biocompatibility and prolonged circulation time owed to the lipids, have recently emerged as a superior alternative to polymeric nanoparticles. Drug nanoparticle complex prepared by electrostatic interaction of oppositely charged drug and polyelectrolytes represents another type of polymeric nanoparticle. This chapter details the preparation, characterization, and antibiofilm efficacy testing of antibiotic-loaded polymeric and hybrid nanoparticles and antibiotic nanoparticle complex.

Key words

Antibiofilm Lipid–polymer hybrid nanoparticles Antimicrobial testing PLGA 

References

  1. 1.
    Stewart PS (2002) Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292:107–113PubMedCrossRefGoogle Scholar
  2. 2.
    Meers P, Neville M, Malinin V et al (2008) Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 61:859–868PubMedCrossRefGoogle Scholar
  3. 3.
    Albanese A, Tang PS, Chan WCW (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16PubMedCrossRefGoogle Scholar
  4. 4.
    Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Peer D, Karp JM, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang L, Chan JM, Gu FX et al (2008) Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–1702PubMedCrossRefGoogle Scholar
  7. 7.
    Cheow WS, Hadinoto K (2012) Green amorphous nanoplex as a new supersaturating drug delivery system. Langmuir 28:6265–6275PubMedCrossRefGoogle Scholar
  8. 8.
    Govender T, Stolnik S, Garnett MC et al (1999) PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57:171–185PubMedCrossRefGoogle Scholar
  9. 9.
    Sung J, Padilla D, Garcia-Contreras L et al (2009) Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 26: 1847–1855PubMedCrossRefGoogle Scholar
  10. 10.
    Cheow WS, Hadinoto K (2011) Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B Biointerfaces 85:214–220PubMedCrossRefGoogle Scholar
  11. 11.
    Harrison J, Ceri H, Yerly J et al (2006) The use of microscopy and three-dimensional visualization to evaluate the structure of microbial biofilms cultivated in the calgary biofilm device. Biol Proced Online 8: 194–215PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Ceri H, Olson ME, Stremick C et al (1999) The calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37: 1771–1776PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Chemical and Biomolecular EngineeringSchool of Chemical and Biomedical Engineering, Nanyang Technological UniversitySingaporeSingapore

Personalised recommendations